Viewing data from:

QWO

BLA

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES | B761146 | ENDO GLOBAL AESTHETICS LTD

2 products0 Purple Book patents

Biologic LOEProtected

Estimated date when biosimilar competition may begin

July 6, 2032(2195 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Jul. 6, 2032	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761146 | 2 presentations

351(a) ReferenceLicensedCDERFor Injection

Proper Name

collagenase clostridium histolyticum-aaes

Applicant

Endo Global Aesthetics Limited

Approval Date

6-Jul-20

.92MG — Single-Dose Vial (Subcutaneous)

1.84MG — Single-Dose Vial (Subcutaneous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 8, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 0.92MG/VIAL

▴

SOLUTION;SUBCUTANEOUS | Approved: 2020-07-06 00:00:00

No patent or exclusivity listings for this strength.

#002 — 1.84MG/VIAL

▾

SOLUTION;SUBCUTANEOUS | Approved: 2020-07-06 00:00:00